Skip to content

Study · Randomized controlled trial · n = 344 · 2010

5 results

GnRH agonist administration at the time of implantation does not improve pregnancy outcome in intrauterine insemination cycles: a randomized controlled trial.

Bellver J, Labarta E, Bosch E, Melo MA, Vidal C, Remohí J, Pellicer A

Fertility and sterility6 Jun 2009Cited by 8 (Europe PMC)

PMID19501354 (opens in a new tab)DOI10.1016/j.fertnstert.2009.04.044 (opens in a new tab)PepBankPUB-19501354
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women undergoing IUI, triptorelin did not significantly change pregnancy rate compared with placebo.

    In plain wordsIn women undergoing IUI, triptorelin did not significantly change pregnancy rate compared with placebo.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePregnancy rate
    Study

    n = 344

    Comparator
    Solvent placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg · subcutaneous · Single injectionAs given in this study (human).

    Measurements

    Pregnancy rate
    22.7%
    triptorelin
    Pregnancy rate
    22.1%
    placebo

    Source sentences

    Summary
    Pregnancy rate per randomized patient was similar in both groups (22.7% vs. 22.1%), as were clinical pregnancy, miscarriage, and ongoing pregnancy rates.
    2 context sentences
    Summary · context
    Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication.
    Summary · context
    Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n=172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women undergoing IUI, clinical pregnancy rates were similar with triptorelin and placebo.

    In plain wordsIn women undergoing IUI, clinical pregnancy rates were similar with triptorelin and placebo.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeClinical pregnancy rate
    Study

    n = 344

    Comparator
    Solvent placebo
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg · subcutaneous · Single injectionAs given in this study (human).

    Source sentences

    Summary
    Pregnancy rate per randomized patient was similar in both groups (22.7% vs. 22.1%), as were clinical pregnancy, miscarriage, and ongoing pregnancy rates.
    2 context sentences
    Summary · context
    Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication.
    Summary · context
    Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n=172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time.
  3. 03HumanRandomized controlled trialSafety outcome

    In women undergoing IUI, miscarriage rates were similar with triptorelin and placebo.

    In plain wordsIn women undergoing IUI, miscarriage rates were similar with triptorelin and placebo.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeMiscarriage rate
    Study

    n = 344

    Comparator
    Solvent placebo
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg · subcutaneous · Single injectionAs given in this study (human).

    Source sentences

    Summary
    Pregnancy rate per randomized patient was similar in both groups (22.7% vs. 22.1%), as were clinical pregnancy, miscarriage, and ongoing pregnancy rates.
    2 context sentences
    Summary · context
    Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication.
    Summary · context
    Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n=172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women undergoing IUI, ongoing pregnancy rates were similar with triptorelin and placebo.

    In plain wordsIn women undergoing IUI, ongoing pregnancy rates were similar with triptorelin and placebo.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeOngoing pregnancy rate
    Study

    n = 344

    Comparator
    Solvent placebo
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg · subcutaneous · Single injectionAs given in this study (human).

    Source sentences

    Summary
    Pregnancy rate per randomized patient was similar in both groups (22.7% vs. 22.1%), as were clinical pregnancy, miscarriage, and ongoing pregnancy rates.
    2 context sentences
    Summary · context
    Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication.
    Summary · context
    Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n=172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women undergoing IUI, the proportion of multiple pregnancies was lower with triptorelin than with placebo.

    In plain wordsIn women undergoing IUI, multiple pregnancies formed a smaller proportion with triptorelin than with placebo.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseMultiple pregnancy proportion
    Study

    n: not reported in source

    Comparator
    Solvent placebo
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1 mg · subcutaneous · Single injectionAs given in this study (human).

    Measurements

    Multiple pregnancies
    10.3%
    triptorelin
    Multiple pregnancies
    36.8%
    placebo

    Source sentences

    Summary
    There was a significant increase in the proportion of multiple pregnancies in the placebo group (10.3% vs. 36.8%).
    2 context sentences
    Summary · context
    Three hundred forty-four women undergoing IUI owing to mild to moderate male factor or donor sperm indication.
    Summary · context
    Random administration to either a single subcutaneous injection of 0.1 mg triptorelin (group A; n=172) 8 days after hCG administration, or solvent only (group B; n=172) at the same time.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.